CS
KURA icon

Credit Suisse’s Kura Oncology KURA Stock Holding History

Credit Suisse’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.55M Buy
72,494
+3,292
+5% +$64K ﹤0.01% 2019
2023
Q4 		$995K Sell
69,202
-2,690
-4% -$26.5K ﹤0.01% 2337
2023
Q3 		$656K Sell
71,892
-7,718
-10% -$78.4K ﹤0.01% 2536
2023
Q2 		$842K Buy
79,610
+7,706
+11% +$91.1K ﹤0.01% 2507
2023
Q1 		$879K Buy
71,904
+6,856
+11% +$85.6K ﹤0.01% 2409
2022
Q4 		$807K Buy
65,048
+12,289
+23% +$179K ﹤0.01% 2483
2022
Q3 		$721K Buy
52,759
+5,661
+12% +$87.3K ﹤0.01% 2567
2022
Q2 		$863K Sell
47,098
-3,552
-7% -$51.1K ﹤0.01% 2492
2022
Q1 		$815K Buy
50,650
+1,267
+3% +$18.3K ﹤0.01% 2665
2021
Q4 		$692K Buy
49,383
+5,938
+14% +$96.2K ﹤0.01% 3593
2021
Q3 		$814K Sell
43,445
-14,282
-25% -$269K ﹤0.01% 3488
2021
Q2 		$1.2M Buy
57,727
+15,625
+37% +$388K ﹤0.01% 3246
2021
Q1 		$1.19M Sell
42,102
-601,022
-93% -$19M ﹤0.01% 3213
2020
Q4 		$21M Buy
643,124
+32,574
+5% +$1.14M 0.01% 1142
2020
Q3 		$18.7M Buy
610,550
+547,762
+872% +$12.1M 0.01% 1058
2020
Q2 		$1.02M Buy
62,788
+47,059
+299% +$679K ﹤0.01% 2893
2020
Q1 		$157K Sell
15,729
-27,283
-63% -$312K ﹤0.01% 3724
2019
Q4 		$591K Buy
43,012
+20,559
+92% +$305K ﹤0.01% 3459
2019
Q3 		$341K Buy
22,453
+3,371
+18% +$60K ﹤0.01% 3638
2019
Q2 		$375K Buy
19,082
+4,731
+33% +$78.5K ﹤0.01% 3567
2019
Q1 		$238K Buy
14,351
+1,518
+12% +$23.4K ﹤0.01% 3704
2018
Q4 		$180K Sell
12,833
-5,309
-29% -$70.3K ﹤0.01% 3689
2018
Q3 		$318K Buy
18,142
+4,869
+37% +$93.3K ﹤0.01% 3493
2018
Q2 		$241K Buy
+13,273
New +$225K ﹤0.01% 3703
2017
Q4 		– Sell
-12,761
Closed -$190K – 4111
2017
Q3 		$190K Buy
+12,761
New +$120K ﹤0.01% 3944

Other funds holding KURA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Credit Suisse's KURA Position: Q1 2024 in Review

Credit Suisse increased its Kura Oncology (KURA) stake by 4.8% in Q1 2024, buying an estimated $64K and bringing the position to 72,494 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #2019.

Credit Suisse first reported a position in KURA in Q3 2017 and has held it in 25 quarters since. The position peaked at $21M in Q4 2020. 165 funds tracked by Wall St. Rank hold KURA as of Q1 2024.

  • Credit Suisse held 72,494 shares of Kura Oncology worth $1.55M as of Q1 2024.
  • Credit Suisse bought 3,292 Kura Oncology shares in Q1 2024, an estimated $64K.
  • Kura Oncology made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2019 holding.
  • Credit Suisse first reported a position in Kura Oncology in Q3 2017 and has held it in 25 quarters since.
  • Credit Suisse's Kura Oncology position peaked at $21M in Q4 2020.
  • 165 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.